###### Strengths and limitations of this study

-   To the best of our knowledge, the economic analysis presented in the article is the first one concerning NEPA within the Italian context.

-   The analysis conducted assessed the efficiency in resources allocation and the sustainability of antiemetic prophylaxis for patients receiving chemotherapy, which is a relevant topic in a field, as that of Oncology, in which a synthesis of effectiveness and cost containment strategies is necessary to allow accessibility of high-cost therapies.

-   The generalisability of results might be limited, since the analysis was conducted concerning the Italian context.

-   The Markov model used does not allow a probabilistic sensitivity analysis to be performed.

Introduction {#s1}
============

Nausea and vomiting still remain among the most feared side effects of cancer chemotherapy.[@R1] A suboptimal control of chemotherapy-induced nausea and vomiting (CINV) can lead to delays in treatment and increase healthcare costs due to increased medication use, hospital admissions and longer hospital stays.[@R2] Ultimately, the consequences of uncontrolled CINV can adversely impact on patient\'s quality of life.[@R3]

The intensity, onset and duration of CINV depend on the emetogenic potential and dose of anticancer agents as well as on individual patient characteristics.[@R2] Highly emetogenic chemotherapy (HEC) such as cisplatin-containing regimens can result in acute emesis (within 24 hours after chemotherapy administration) in more than 90% of patients without antiemetics.[@R4] Agents such as carboplatin, oxaliplatin, cyclophosphamide or anthracyclines (eg, doxorubicin or epirubicin) carry a moderate emetic risk (incidence of acute emesis without antiemetics, 30%--90%) as single agents but their combination may increase emetic risk substantially.[@R4] The current guideline-recommended prophylaxis for patients receiving HEC is a three-drug regimen including a 5-HT~3~ receptor antagonist (5-HT~3~RA), dexamethasone and a neurokinin-1 receptor antagonist (NK-1RA).[@R5] In patients receiving moderately emetogenic chemotherapy (MEC), the combination of a 5-HT~3~RA and dexamethasone is the current guideline-recommended regimen for the prevention of CINV.[@R4] It also should be noted that some guidelines recommend palonosetron (PALO) as the preferred 5-HT~3~RA in the setting of MEC.[@R6] More recently, it has been recognised that although carboplatin is graded as moderately emetogenic in evidence-based guidelines, the emetogenic potential of this agent is at the higher end of MEC.[@R8] Accordingly, the updated guidelines from the Multinational Association of Supportive Care in Cancer now recommend a three-drug regimen for the optimal control of CINV following carboplatin-based chemotherapy.[@R4]

Emerging from the most recent research on CINV is netupitant+palonosetron (NEPA), the first antiemetic combination drug developed. NEPA is a single oral fixed-dose combination of netupitant, a new NK-1RA with a long half life of 90 hours and PALO.[@R9] PALO is a second-generation 5-HT~3~RA that has greater 5-HT~3~ receptor binding affinity and longer plasma elimination half life compared with older antagonists and a unique interaction with the 5-HT~3~ receptor at the molecular level. The unique pharmacology of PALO is thought to partly explain its improved efficacy against delayed CINV.[@R10] It must be pointed out that NEPA is capable of enhancing the convenience of administering antiemetic prophylaxis targeted at two critical molecular pathways involved in the pharmacology of CINV.[@R2] Large-scale clinical trials have demonstrated that NEPA plus dexamethasone was superior to the control combination of PALO and dexamethasone, as measured by the proportion of patients with a complete response (CR) throughout the 5-day period after the first cycle of either cisplatin-containing chemotherapy or the high-emetic-risk combination of an anthracycline and cyclophosphamide (AC) in patients with breast cancer.[@R11] It must be pointed out that the combination of AC has historically been considered a MEC regimen but because it is commonly administered to females with breast cancer, the emetogenic risk is substantially increased due to the additional patient-related risk factors (i.e., gender and age).[@R2] Since an effective and convenient antiemetic prophylaxis that preserves benefit over repeated cycles of chemotherapy is a clinically important topic,[@R13] a double-blind, randomised phase III trial investigated the safety and efficacy of NEPA in this challenging setting.[@R15] This study demonstrated sustained efficacy over repeated cycles of HEC or MEC in patients treated with NEPA. More recently, a multiple-cycle extension of the phase III trial with NEPA in patients with breast cancer receiving AC also showed the sustained benefit of NEPA over multiple cycles of therapy.[@R16]

The assessment of the effectiveness and safety of new treatments are two of the key dimensions that should be evaluated in the assessment of new technology. However, further impacts of the introduction of a new medicine on health services should be assessed, assuming a multidisciplinary approach as that of Health Technology Assessment (HTA).[@R17] Within a complete HTA, the 'costs and economic evaluation' represents one of the key dimensions to be considered. The assessment of this dimension is crucial considering the context in which National Health Services worldwide are operating, characterised by a persistent stress on national healthcare budgets (i.e., austerity measures)[@R18] and the need to make new and effective health technologies available to patients. Due to a lack of economic evaluation within the Italian National Health Service and the aforementioned considerations, the analysis presented aimed at evaluating the efficiency of resources allocation and sustainability of the use of NEPA in the management of the prophylaxis of CINV in the Italian context, both for HEC (cisplatin) and MEC (AC and non-AC MEC), through a cost-utility analysis and a budget impact analysis.

Methods {#s2}
=======

Cost-utility analysis {#s2a}
---------------------

### Cost-utility model, perspective and model outcomes {#s2a1}

The assessment of the incremental cost-utility ratio (ICUR) of the use of NEPA versus the comparators was performed using a Markov model already used in an analysis presented in literature,[@R19] whose structure is reported in [figure 1](#F1){ref-type="fig"}. The perspective assumed in the analysis was that of the Italian National Health Service (NHS).

![Markov model structure. CINV, chemotherapy-induced nausea and vomiting.](bmjopen-2016-015645f01){#F1}

The model considers a single cycle of chemotherapy, with a 5-day time horizon for CINV management (no discount rate was used due to the time horizon considered) and the possibility for patients to transit through three mutually exclusive health states: 'complete protection (CP)' (absence of emetic episodes, no significant nausea (\<25 mm on a Visual Analogue Scale)and no use of rescue medication), 'CR' (absence of emetic episodes and no use of rescue medication) and 'incomplete response' (patients experiencing emesis and requiring rescue medication).

Patients who start an antiemetic prophylaxis for CINV may reach a 'CP', 'CR' or 'Incomplete response' state in the acute phase (day 1). On day 5, the distribution of patients among the health states is based on the effectiveness parameters of the overall phase (day 1--5). During the second, third and fourth day, the distribution of patients among the health states was calibrated using linear interpolation between the response proportion of the acute and overall phase.

In the delayed phase (days 2--5), patients may remain in the same health state of the previous cycle or transit to 'CR' from the 'CP' state and transit to 'Incomplete response' state from the 'CP' and 'CR' health states.[@R19]

The transition probabilities depend on the effectiveness parameters considered per treatment in the acute phase and delayed phase.

During the 5-day time horizon of the analysis, patients may experience adverse events, with a probability derived from clinical trials and published studies.

The outcome of the model is the ICUR of the use of NEPA compared with each comparator. This represents the incremental cost associated with each additional unit of utility (either a QALY or a quality adjusted life day (QALD)).

Interventions, eligible population and time horizon {#s2b}
---------------------------------------------------

The cost-utility analysis was conducted considering the use of NEPA both in patients receiving HEC and MEC, comparing the use of the new drug with the administration of NK1-RA (aprepitant (APR) or fosaprepitant (fAPR)) in combination with 5HT3-RA (PALO or ondansetron (ONDA)). The time horizon considered in the analysis is of 5 days.

Model parameters {#s2c}
----------------

### Clinical efficacy analysis {#s2c1}

The estimates of changes in the probability of CINV control over repeated cycles of HEC or MEC were obtained from a double-blind, randomised trial of NEPA-based (day 1: NEPA plus dexamethasone) and APR-based (day 1: APR 125 mg, PALO 0.50 mg and dexamethasone; days 2--3: APR 80 mg per day) antiemetic regimens for the prevention of CINV among chemo-naïve, adult patients with a malignancy who were scheduled to receive repeated consecutive cycle of chemotherapy. The study design has been previously described in detail.[@R15] Four hundred and twelve patients (for a total of 1961 chemotherapy cycles, 1446 in the NEPA arm and 515 in the APR + PALO arm) were eligible, being scheduled to receive HEC or non-AC MEC regimens. The goal of the study was to characterise the safety profile of NEPA over at least six consecutive cycles of chemotherapy. Efficacy end points were CR (defined as no emesis and no rescue medication) and CP (defined as no emesis, no rescue medication and no significant nausea (Visual Analogue Scale score of \<25 mm)) during the acute (within 24 hours after chemotherapy administration) and overall (within 5 days after chemotherapy initiation) periods after all planned chemotherapy cycles.

The proportion of patients with either CR or CP was used to evaluate efficacy across acute and overall phases. To accurately determine protection against CINV over multiple consecutive cycles, a generalised mixed linear model was used. In detail, the overall proportions and proportions at each chemotherapy cycle of CR and CP, with associated two-tailed 95% CIs, were estimated using a model with an identity link function (non-canonical link function), binomial probability distribution and parameterised with treatment group, cycle and treatment-by-cycle interaction as fixed effects.[@R20] Overall CR and CP proportions were estimated directly from the generalised mixed linear model as least-square mean of the fixed effect 'treatment group'. Since incomplete profiles may occur because of the physician\'s decision to administer fewer than six cycles or because of drop-out events, the mixed model was parameterised using a full Toeplitz variance--covariance matrix. This should represent a suitable choice to take into account correlation across repeated measures (cycles) and to adjust for the potential bias caused by incomplete profiles. Computations were performed using the GLIMMIX procedure of SAS version 9.4.

The adjusted proportion estimates of achieving CINV control in each treatment arm during the acute and overall periods among patients receiving a cycle of HEC or MEC are presented in the online [supplementary material](#SP1){ref-type="supplementary-material"}.
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The effectiveness parameters considered for NEPA are reported in [table 1](#T1){ref-type="table"}, along with the Odds Ratios (ORs) for each comparator, derived from the results of the NEPA study in HEC[@R11] and from the results of NEPA study in MEC[@R12]). The effectiveness parameters of NEPA, are based on the following clinical trials: the NEPA study in patients receiving either HEC or MEC[@R15] and within the sensibility analysis, the NEPA studies in HEC[@R11] and MEC.[@R12]

###### 

NEPA effectiveness and ORs considered in the model

  .                     Effectiveness       NEPA versus                                   
  --------------------- ------------------- ------------------- -------- -------- ------- -------
  HEC                   Acute phase         Complete response   92.8     1.952‡   7.540   3.602
  Complete protection   90.0                2.536‡              4.619    3.753            
  Overall phase         Complete response   83.6                1.982‡   2.647    1.333   
  Complete protection   78.0                2.064‡              2.102    1.345            
  MEC                   Acute phase         Complete response   95.7     0.956‡   1.345   N/A
  Complete protection   92.8                1.099‡              1.084    N/A              
  Overall phase         Complete response   88.1                1.248‡   1.450    N/A     
  Complete protection   83.5                1.336‡              1.281    N/A              

Due to the clinical non-inferiority of fAPR compared with APR and to a lack of data referred to therapies that imply the use of fAPR, the same ORs of APR based therapies were considered for fAPR + PALO and fAPR + ONDA.

\*Considered for the budget impact analysis.

†HEC: data calculated on the basis of the results from reference \[[@R11]\]; MEC: data calculated on the basis of the results of reference \[[@R12]\].

‡Data calculated on the basis of the results from reference \[[@R15]\].

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron.

Starting from the effectiveness results of NEPA derived from the aforementioned clinical trial, ORs were calculated to be incorporated in the model for each comparator, as reported in [table 1](#T1){ref-type="table"}. Due to the clinical non-inferiority of fAPR compared with APR and to a lack of data referred to therapies that consider the use of fAPR, the same ORs of APR based therapies were considered.

The adverse events considered were constipation, headache, fatigue, injection site\'s reaction, anorexia. The incidence of each adverse event is reported in [table 2](#T2){ref-type="table"}.

###### 

Adverse events\' incidence

  Therapy       Chemotherapy   Constipation   Headache   Fatigue   Injection site\'s reaction   Anorexia
  ------------- -------------- -------------- ---------- --------- ---------------------------- ----------
  NEPA          HEC            2.3%a          1.0%a      4.0%b     0.0%c                        0.7%d
  MEC           2.3%a          1.0%a          4.0%b      0.0%c     0.7%d                        
  APR + PALO    HEC            0.0%e          1.0%e      1.4%e     0.0%f                        2.0%e
  MEC           0.0%e          1.0%e          1.4 %e     0.0%f     2.0%e                        
  APR + ONDA    HEC            2.4%e          2.0%e      1.4 %e    0.0%\*                       2.0%e
  fAPR + PALO   HEC            2.4%e          2.0%e      1.4 %e    3.0%g                        2.0%e
  MEC           2.4%e          2.0%e          1.4 %e     35.0%g    2.0%e                        
  fAPR + ONDA   HEC            2.4%e          1.5%d      1.4 %e    3.0%g                        2.0%e
  PALO          HEC            0.0%\*†        1.5%d†     2.0 %b†   0.0%f†                       2.2%d†
  MEC           0.0%\*†        1.5%d†         2.0 %b†    0.0%f†    2.2%d†                       

a.[@R26]; b.[@R27]; c.[@R28]; d.[@R29]; e.[@R30]; f.[@R31]; g.[@R32].

\*Equal to 0.0% assuming a conservative approach.

†Considered for the budget impact analysis.

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron.

Costs {#s2d}
-----

The costs considered in the analysis are direct medical costs referred to year 2016 related to the antiemetic therapy administered to patients, the management of adverse events and the management of CINV episodes.

The costs related to each antiemetic drug, including the mandatory discount for the National Health Service are presented in [table 3](#T3){ref-type="table"}, along with the cost per adverse event management and CINV episode management.

###### 

Costs considered in the analysis

  -----------------------------------------------------------------------------------------------------------
  Cost category             Cost per cycle/event\   Notes                                     Source
                            (€)                                                               
  ------------------------- ----------------------- ----------------------------------------- ---------------
  NEPA (oral)\*             90.46                   Netupitant 300 mg + PALO 0.5 mg capsule   [@R33]

  APR (oral)\*              49.48                   1×125 mg capsule+2×80 mg capsules         [@R34]

  fAPR (intravenous)\*      48.41                   150 mg vial                               [@R35]

  ONDA (intravenous)\*      23.00                   4x8 mg vial                               [@R36]

  PALO (intravenous)\*      43.21                   0.25 mg vial                              [@R37]

  dexamethasone             0.12                    Cost per mg                               [@R38]

  CINV episode              33.49†                                                            KOL interview

  Constipation              0.00                                                              KOL interview

  Headache                  0.00                                                              KOL interview

  Fatigue                   0.00                                                              KOL interview

  Injection site reaction   62.52‡                                                            KOL interview

  Anorexia                  273.00§                                                           KOL interview
  -----------------------------------------------------------------------------------------------------------

For HEC, dexamethasone doses considered are: 12 mg in day 1 and 8 mg on day 2, 3 and 4 for NEPA, APR + PALO, APR + ONDA; 12 mg on day 1, 8 mg in day 2 and 16 mg on day 3 and 4 for fAPR + PALO, fAPR + ONDA; 20 mg on day 1 and 16 mg on day 2, 3 and 4 for PALO.

For MEC the dexamethasone doses considered are: 12 mg on day 1 for NEPA, APR + PALO, fAPR + PALO, APR + ONDA, fAPR + ONDA and 20 mg on day 1 for PALO.

\*Costs are inclusive of mandatory legal discounts.

†Equivalent to a day of hospitalisation as for 'anorexia' in 2% of patients, multiplied by 5 (the hospitalisation may be repeated up to five times); a rescue medication for 10% of patients (ondansetron + metoclopramide) and a specialist visit for 5% of patients (<http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto>).

‡Equivalent to the cost of 1 cannula, 30 min of nursing time, 30 min of pharmacist time and for 15% of patients, a central venous catheter positioning (code 38.95) (<http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto>).

§Equivalent to a day of hospitalisation for 'Nutrition disorders and miscellaneous metabolic disorders, \>17 years old without complications (DRG 297)' (<http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3662&area=programmazioneSanitariaLea&menu=vuoto>).

APR, aprepitant; CINV, chemotherapy-induced nausea and vomiting; fAPR, fosaprepitant; ONDA, ondansetron; PALO, palonosetron.

The cost for the management of adverse events and CINV episode are based on real clinical practice, as emerged from interviews conducted with a Key Opinion Leader clinician referring to the Department of Medical Oncology of an oncology research hospital ('Istituto di Ricovero e Cura a Carattere Scientifico') based in Milan. CINV management took into consideration a weighted mean cost which considered hospitalisations, rescue medication and outpatient activities. The management of adverse events took into consideration hospitalisations, outpatient activities and drugs. Assuming the Italian National Health Service point of view, all out-of-pocket expenditures for the management of adverse events were not considered, leading to cost equal to €0 for three of the adverse events considered in the analysis.

A further cost of €20.66 (reimbursement due to a specialist visit) was considered for intravenous administration of drugs, due to the hospital resources' increased use compared with oral administration of therapies.

Utility {#s2e}
-------

Utility was measured considering the QALYs gained by patients due to the use of antiemetic therapies. Due to the short-term time horizon considered, to increase the readability of the results, QALDs were used.

The quality of life of patients is affected in the model by health state and adverse events. The utility and disutility values considered are presented in [table 4](#T4){ref-type="table"}.

###### 

Utility and disutility values affecting quality of life

  Health state/adverse event   Health states' utility values/adverse events' disutility values   Source
  ---------------------------- ----------------------------------------------------------------- --------
  Complete protection          0.77                                                              [@R39]
  Complete response            0.60                                                              [@R40]
  Incomplete response          0.26                                                              [@R40]
  Constipation                 --0.06                                                            [@R42]
  Headache                     --0.20                                                            [@R43]
  Fatigue                      --0.12                                                            [@R44]
  Injection site\'s reaction   --0.01                                                            [@R45]
  Anorexia                     --0.18                                                            [@R46]

Sensitivity analysis {#s2f}
--------------------

A univariate sensitivity analysis was conducted to test the robustness of the results. The parameters changed were the cost of NEPA (±10%), the cost of intravenous administration (assumed to be equal to €0), the cost of adverse events (assumed to be equal to €0 and increasing the cost of adverse events managed with out-of-pocket resources to be equal to that of the less expensive adverse event considered), the cost of CINV event (±20%), the utility values associated with health states (±20%), the disutility values associated with adverse events (±20%). A further sensitivity analysis was conducted varying the price of PALO to assess at which extent its variation could modify the results of the analysis.

Budget impact analysis {#s2g}
----------------------

### Budget impact, perspective and time horizon {#s2g1}

The assessment of the sustainability of the use of NEPA in the Italian context was performed using a budget impact model comparing the direct medical costs related to antiemetic therapies, the management of CINV episodes and related adverse events ([table 2](#T2){ref-type="table"}) of two scenarios: one that did not considered the use of NEPA and one that considered the use of the new drug. The difference between the costs of the two scenarios is the impact on the budget of the Italian National Health Service due to the introduction of NEPA. The analysis was performed considering a 5-year time horizon (between 2016 and 2020).[@R21]

Target population, interventions' mix and market shares {#s2h}
-------------------------------------------------------

The size of the target population considered was based on the incidence in Italy in 2012 of lung cancer, head and neck cancer, stomach cancer, testicular cancer and bladder cancer for patients receiving HEC; breast cancer, colorectal cancer, ovarian cancer, lung cancer, stomach cancer, pancreatic cancer for patients receiving MEC.[@R22] The number of cycles for which NEPA might be eligible for use was derived from the international oncology guidelines of the \@sco project.[@R23]

Due to the lack of comparative data of the use of NEPA versus ONDA for patients receiving HEC and MEC and of NEPA versus APR + ONDA and versus fAPR + ONDA for patients receiving MEC, the annual number of cycles of chemotherapies considered excludes the ones assigned to the aforementioned antiemetic treatments (ONDA for HEC and MEC; APR + ONDA and fAPR + ONDA for MEC). The market shares of each antiemetic treatment were derived starting from market analysis and KOL opinions and are reported along with the number of chemotherapy cycles considered for patients receiving HEC and MEC in the online [supplementary material](#SP1){ref-type="supplementary-material"}.

Resource used and costs {#s2i}
-----------------------

The resource used and the related costs are the same presented in the previous section ('cost-utility analysis').

Sensitivity analysis {#s2j}
--------------------

A univariate sensitivity analysis was conducted to test the robustness of the results modifying the following parameters: effectiveness emerged in the NEPA study in HEC[@R11] and the NEPA study in MEC,[@R12] cost of NEPA (±10%), cost of adverse events (assumed to be equal to €0 and increasing the cost of adverse events managed with out-of-pocket resources to be equal to that of the less expensive adverse event considered), cost of CINV event (±20%).

Results {#s3}
=======

Cost-utility analysis {#s3a}
---------------------

The use of NEPA lead to a decrease of direct medical costs and to an increase of QALDs compared with APR + PALO and fAPR + PALO for patients receiving both HEC and MEC and to a decrease of direct medical costs and to an increase of QALDs compared with APR + ONDA and fAPR + ONDA for patients receiving HEC, as reported in [table 5](#T5){ref-type="table"}.

###### 

Results of the cost-utility analysis

  Chemotherapy   Antiemetic therapy   Mean cost (€)   Incremental cost (€)   Mean QALDs   Incremental QALDs   Incremental cost-utility ratio (€/QALD)
  -------------- -------------------- --------------- ---------------------- ------------ ------------------- -----------------------------------------
  HEC            APR + PALO           132.5           --                     2.684        --                  NEPA is dominant
  NEPA           102.4                −30.2           2.945                  +0.261                           
  APR + ONDA     148.8                --              3.020                  --           NEPA is dominant    
  NEPA           100.4                −48.4           3.097                  +0.077                           
  fAPR + PALO    155.3                --              2.684                  --           NEPA is dominant    
  NEPA           102.4                --52.9          2.945                  +0.261                           
  fAPR + ONDA    171.7                --              3.020                  --           NEPA is dominant    
  NEPA           100.4                −71.4           3.097                  +0.077                           
  MEC            APR + PALO           125.1           --                     2.992        --                  NEPA is dominant
  NEPA           97.9                 −27.2           3.044                  +0.052                           
  fAPR + PALO    145.9                --              2.992                  --           NEPA is dominant    
  NEPA           97.9                 −48.0           3.044                  +0.052                           

APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron; QALD, quality adjusted life day.

NEPA dominates APR + PALO, fAPR + PALO, APR + ONDA and fAPR + ONDA in patients receiving HEC and dominates APR + PALO, fAPR + PALO in patients receiving MEC.

The sensitivity analysis conducted confirmed the robustness of the results, leading to a domination of NEPA in all the scenario considered, excluding the one in which no intravenous administration cost is considered in the analysis with APR + ONDA, in which NEPA would lead to an increase of costs and to an increase of QALDs. To evaluate whether NEPA is cost effective compared with APR + ONDA for patients receiving HEC, the €/QALD cost-utility ratio was converted in €/QALY. The result shows an ICUR of €64 329/QALY. The ICUR within the population receiving HEC is on the acceptability threshold value of €40 000/QALY identified by the Italian Association of Health Economics;[@R24] therefore, NEPA is not cost-effective compared with APR + ONDA in the scenario that does not consider the resources used by hospitals for intravenous administration of drugs. The dominance of NEPA versus its comparators would not be affected up to a reduction of PALO price of --63%.

Budget impact analysis {#s3b}
----------------------

In terms of impact on the budget of the Italian National Health Service, the use of NEPA is likely to lead to an annual cost decrease both for patients receiving HEC and MEC. NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for patients receiving HEC and €20.9 million for patients receiving MEC). The decrease of costs for the Italian National Health Service is due to the increased use of NEPA over the years, being €--2.7 million in 2016, €--7.1 million in 2017, €--9.0 million in 2018, €--11.2 million in 2019, €--12.7 million in 2020 for patients receiving HEC; €--1.4 million in 2016, €--2.5 million in 2017, €--3.7 million in 2018, €--5.5 million in 2019, €--7.9 million in 2020 for patients receiving MEC and €-- 4.1 million in 2016, €--9.6 million in 2017, €--12.7 million in 2018, €--16.7 million in 2019, €--20.5 million in 2020 for the whole target population (HEC + MEC). The budget impact analysis results are presented in [figure 2](#F2){ref-type="fig"}.

![Budget impact analysis results.](bmjopen-2016-015645f02){#F2}

The results of the sensitivity analysis show a minimum 5 years budget impact of €--49.0 million for the whole population (HEC + MEC) in the scenario that does not consider the cost of adverse events and a maximum 5 years budget impact of €--83.9 million in the scenario that considers a reduction of the cost of NEPA of 10%. The use of NEPA would lead to a decrease of costs for the Italian National Health Service in each year of the analysis in every scenario.

Discussion and conclusion {#s4}
=========================

The cost-utility analysis showed a dominance of NEPA (decreasing costs and increasing incremental QALDs) in patients receiving HEC compared with APR + PALO, fAPR + PALO, APR + ONDA and fAPR + ONDA and in patients receiving MEC compared with APR + PALO and fAPR + PALO.

In terms of sustainability of the investment, the use of NEPA would lead to a decrease of direct medical costs for the Italian National Health Service for the management of patients receiving HEC and MEC on a 5-year basis between €--49.0 million and €−83.9 million.

The sensitivity analyses conducted confirmed the robustness of results.

To our knowledge, the only economic analysis published so far concerning the use of NEPA is a poster presentation by D'Agostino and colleagues[@R19] in which a cost effectiveness analysis was conducted comparing NEPA with APR + PALO and with PALO to prevent CINV in HEC and MEC patients in UK. NEPA dominates both APR + PALO in patients treated with HEC and PALO in patients treated with MEC and would lead to lower costs for the British NHS on a 5-year time horizon equal to £13.98 million. The results of the aforementioned study are consistent with the findings of our analysis. The lower budget impact reduction of the British study is related to the lower number of market shares considered in terms of market penetration of NEPA, due to the lower number of comparators considered. However, since drugs acquisition costs may vary considerably between countries, as the frequency of CINV episodes, international comparisons should be taken with caution. As an example, Turini and colleagues[@R25] estimated the direct medical costs of severe CINV episodes requiring hospitalisation in three European countries, with an average cost of €389.0 in Italy, €750.1 in France and €1016.7 in Germany.

The analysis presented took into consideration an important topic as that of antiemetic prophylaxis for patients receiving chemotherapy. The importance of antiemetic prophylaxis is not only related to the possibility to avoid chemotherapies' adverse events with positive effects on the quality of life of patients, on the quality of the health services' performed and on patient\'s management costs. The lack of prophylaxis, in fact, may lead to future anticipatory emetic events, increasing the adverse events of important and severe therapies as chemotherapy. Furthermore, such anticipatory events, might lead to further prescriptions of tranquilliser and antidepressant drugs with an increase in the drug burden for patients and of costs for the National Health Service.

Due to the expiration of the patent of PALO, generic version of this molecule might be available on the market soon. This factor would reduce the lower costs associated with the use of NEPA unless a price revision for this drug would be proposed. The sensitivity analysis results of the cost-utility Analysis show that up to a 63% reduction of the price of PALO, NEPA would remain dominant in all scenarios.

In conclusion, being aware of the limitations of the model and of the lack of a probabilistic sensitivity analysis, the use of NEPA for the prophylaxis of CINV within the Italian context would lead to an efficient allocation of resources both for the treatment of patients receiving HEC (being dominant compared with APR + PALO, fAPR + PALO, APR + ONDA and fAPR + ONDA) and MEC (being dominant compared with APR + PALO and fAPR + PALO).

The use of NEPA is sustainable in the Italian context, leading to a reduction of costs for the management of patients receiving HEC and MEC.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

**Contributors:** UR participated in the design of the study, adapted the model, performed the economic analysis and drafted the manuscript. GS, PN, RDT and TP participated to the interpretation of the results and critically revised the article. EB participated in the design of the study, in the model adaptation and helped to draft the manuscript. FS participated in the model adaptation and economic analysis and critically revised the article. DC participated in economic analysis and critically revised the article. LC participated in the design of the study and in the adaptation of the model and helped to draft the manuscript. All authors read and approved the final manuscript.

**Funding:** The analysis and the article drafting were supported by an unconditional grant from Italfarmaco Spa.

**Competing interests:** UR declares advisory board fees from Bayer and Italfarmaco. GS, PN, RDT, FS and DC declare no conflict of interests. EB declares grants from Italfarmaco Spa, Zambon Spa and Polichem SA. TP is employed by Italfarmaco Spa. LC declares personal fees from Italfarmaco Spa and Helsinn Healthcare SA.

**Provenance and peer review:** Not commissioned; externally peer reviewed.
